Epigenetic mechanisms in migraine: a promising avenue?

BMC Medicine

Michel D Ferrari¹  Arn MJM van den Maagdenberg¹  Nicole A Datson²  Else Eising² 

[1]Department of Neurology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands

[2]Department of Human Genetics, Leiden University Medical Centre, Einthovenweg 20, Leiden, 2333 ZC, The Netherlands

关键词: valproate;    stress;    migraine;    inflammation;    histone modifications;    GWAS;    epigenetics;    DNA methylation;   

Others  :  857207
DOI  :  10.1186/1741-7015-11-26

 received in 2012-10-09, accepted in 2013-02-04,  发布年份 2013

【 摘 要 】

Migraine is a disabling common brain disorder typically characterized by attacks of severe headache and associated with autonomic and neurological symptoms. Its etiology is far from resolved. This review will focus on evidence that epigenetic mechanisms play an important role in disease etiology. Epigenetics comprise both DNA methylation and post-translational modifications of the tails of histone proteins, affecting chromatin structure and gene expression. Besides playing a role in establishing cellular and developmental stage-specific regulation of gene expression, epigenetic processes are also important for programming lasting cellular responses to environmental signals. Epigenetic mechanisms may explain how non-genetic endogenous and exogenous factors such as female sex hormones, stress hormones and inflammation trigger may modulate attack frequency. Developing drugs that specifically target epigenetic mechanisms may open up exciting new avenues for the prophylactic treatment of migraine.

【 授权许可】

   
2013 Eising et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]IHS: The International Classification of Headache Disorders. Cephalalgia 2nd edition. 2004, 24(Suppl 1):9-160.
• [2]Goadsby PJ, Lipton RB, Ferrari MD: Migraine-current understanding and treatment. N Engl J Med 2002, 346:257-270.
• [3]Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol 2010, 28:1057-1068.
• [4]Wessman M, Terwindt GM, Kaunisto MA, Palotie A, Ophoff RA: Migraine: a complex genetic disorder. Lancet Neurol 2007, 6:521-532.
• [5]MacGregor EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004, 3:354-361.
• [6]Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S: Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008, 111:127-136.
• [7]Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996, 87:543-552.
• [8]van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, van de Ven RC, Tottene A, van der Kaa J, Plomp JJ, Frants RR, Ferrari MD: A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004, 41:701-710.
• [9]Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C: Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 2009, 119:99-109.
• [10]Gupta S, McCarson KE, Welch KM, Berman NE: Mechanisms of pain modulation by sex hormones in migraine. Headache 2011, 51:905-922.
• [11]Green CD, Han JD: Epigenetic regulation by nuclear receptors. Epigenomics 2011, 3:59-72.
• [12]Ruegg J, Cai W, Karimi M, Kiss NB, Swedenborg E, Larsson C, Ekstrom TJ, Pongratz I: Epigenetic regulation of glucose transporter 4 by estrogen receptor beta. Mol Endocrinol 2011, 25:2017-2028.
• [13]Tan XJ, Dai YB, Wu WF, Kim HJ, Barros RP, Richardson TI, Yaden BC, Warner M, McKinzie DL, Krishnan V, Gustafsson JA: Reduction of dendritic spines and elevation of GABAergic signaling in the brains of mice treated with an estrogen receptor beta ligand. Proc Natl Acad Sci USA 2012, 109:1708-1712.
• [14]Lee ES, Sidoryk M, Jiang H, Yin Z, Aschner M: Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. J Neurochem 2009, 110:530-544.
• [15]Aurora SK, Wilkinson F: The brain is hyperexcitable in migraine. Cephalalgia 2007, 27:1442-1453.
• [16]Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M, van den Maagdenberg AM, Ferrari MD, Pietrobon D: Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron 2009, 61:762-773.
• [17]Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ: Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.
• [18]Hunter RG: Epigenetic effects of stress and corticosteroids in the brain. Front Cell Neurosci 2012, 6:18.
• [19]Kelman L: The triggers or precipitants of the acute migraine attack. Cephalalgia 2007, 27:394-402.
• [20]Tietjen GE, Peterlin BL: Childhood abuse and migraine: epidemiology, sex differences, and potential mechanisms. Headache 2011, 51:869-879.
• [21]Peterlin BL, Nijjar SS, Tietjen GE: Post-traumatic stress disorder and migraine: epidemiology, sex differences, and potential mechanisms. Headache 2011, 51:860-868.
• [22]Heim C, Binder EB: Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol 2012, 233:102-111.
• [23]Tietjen GE, Khubchandani J, Herial NA, Shah K: Adverse childhood experiences are associated with migraine and vascular biomarkers. Headache 2012, 52:920-929.
• [24]Danese A, Pariante CM, Caspi A, Taylor A, Poulton R: Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA 2007, 104:1319-1324.
• [25]Diener HC, Kuper M, Kurth T: Migraine-associated risks and comorbidity. J Neurol 2008, 255:1290-1301.
• [26]Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
• [27]Udali S, Guarini P, Moruzzi S, Choi SW, Friso S: Cardiovascular epigenetics: From DNA methylation to microRNAs. Mol Aspects Med 2012.
• [28]Qureshi IA, Mehler MF: Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis. Neurobiol Dis 2010, 39:53-60.
• [29]Sun H, Kennedy PJ, Nestler EJ: Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013, 38:124-137.
• [30]Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
• [31]Wilkinson MB, Xiao G, Kumar A, LaPlant Q, Renthal W, Sikder D, Kodadek TJ, Nestler EJ: Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009, 29:7820-7832.
• [32]Higuchi F, Uchida S, Yamagata H, Otsuki K, Hobara T, Abe N, Shibata T, Watanabe Y: State-dependent changes in the expression of DNA methyltransferases in mood disorder patients. J Psychiatr Res 2011, 45:1295-1300.
• [33]Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999, 23:185-188.
• [34]Gibbons R: Alpha thalassaemia-mental retardation, X linked. Orphanet J Rare Dis 2006, 1:15. BioMed Central Full Text
• [35]Kobow K, Jeske I, Hildebrandt M, Hauke J, Hahnen E, Buslei R, Buchfelder M, Weigel D, Stefan H, Kasper B, Pauli E, Blumcke I: Increased reelin promoter methylation is associated with granule cell dispersion in human temporal lobe epilepsy. J Neuropathol Exp Neurol 2009, 68:356-364.
• [36]Haas CA, Frotscher M: Reelin deficiency causes granule cell dispersion in epilepsy. Exp Brain Res 2010, 200:141-149.
• [37]Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
• [38]Passaro D, Rana G, Piscopo M, Viggiano E, De Luca B, Fucci L: Epigenetic chromatin modifications in the cortical spreading depression. Brain Res 2010, 1329:1-9.
• [39]Rana G, Donizetti A, Virelli G, Piscopo M, Viggiano E, De Luca B, Fucci L: Cortical spreading depression differentially affects lysine methylation of H3 histone at neuroprotective genes and retrotransposon sequences. Brain Res 2012, 1467:113-119.
• [40]Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, Zhang K, Ming GL, Gao Y, Song H: Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 2011, 14:1345-1351.
• [41]Nelson ED, Monteggia LM: Epigenetics in the mature mammalian brain: effects on behavior and synaptic transmission. Neurobiol Learn Mem 2011, 96:53-60.
• [42]Kunkler PE, Hulse RE, Kraig RP: Multiplexed cytokine protein expression profiles from spreading depression in hippocampal organotypic cultures. J Cereb Blood Flow Metab 2004, 24:829-839.
• [43]Johnson HM, Noon-Song EN, Kemppainen K, Ahmed CM: Steroid-like signalling by interferons: making sense of specific gene activation by cytokines. Biochem J 2012, 445:295.
• [44]Xuan A, Long D, Li J, Ji W, Hong L, Zhang M, Zhang W: Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci 2012, 90:463-468.
• [45]Waeber C, Moskowitz MA: Migraine as an inflammatory disorder. Neurology 2005, 64:S9-15.
• [46]Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ: Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med 2011, 17:1448-1455.
• [47]Schurks M, Rist PM, Kurth T: MTHFR 677C > T and ACE D/I polymorphisms in migraine: a systematic review and meta-analysis. Headache 2010, 50:588-599.
• [48]Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, Nyholt DR, Dimas AS, Freilinger T, Muller-Myhsok B, Artto V, Inouye M, Alakurtti K, Kaunisto MA, Hamalainen E, de Vries B, Stam AH, Weller CM, Heinze A, Heinze-Kuhn K, Goebel I, Borck G, Gobel H, Steinberg S, Wolf C, Bjornsson A, Gudmundsson G, Kirchmann M, Hauge A, Werge T, et al.: Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010, 42:869-873.
• [49]Chasman DI, Schurks M, Anttila V, de Vries B, Schminke U, Launer LJ, Terwindt GM, van den Maagdenberg AM, Fendrich K, Volzke H, Ernst F, Griffiths LR, Buring JE, Kallela M, Freilinger T, Kubisch C, Ridker PM, Palotie A, Ferrari MD, Hoffmann W, Zee RY, Kurth T: Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011, 43:695-698.
• [50]Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, Winsvold B, Nyholt DR, van Oosterhout WP, Artto V, Todt U, Hamalainen E, Fernandez-Morales J, Louter MA, Kaunisto MA, Schoenen J, Raitakari O, Lehtimaki T, Vila-Pueyo M, Gobel H, Wichmann E, Sintas C, Uitterlinden AG, Hofman A, Rivadeneira F, Heinze A, Tronvik E, van Duijn CM, Kaprio J, et al.: Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 2012, 44:777-782.
• [51]Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB: Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res 2008, 68:1478-1484.
• [52]Rampalli S, Li L, Mak E, Ge K, Brand M, Tapscott SJ, Dilworth FJ: p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol 2007, 14:1150-1156.
• [53]Speksnijder N, Christensen KV, Didriksen M, De Kloet ER, Datson NA: Glucocorticoid receptor and myocyte enhancer factor 2 cooperate to regulate the expression of c-Jun in a neuronal context. J Mol Neurosci 2012, 48:209-218.
• [54]Endo K, Karim MR, Taniguchi H, Krejci A, Kinameri E, Siebert M, Ito K, Bray SJ, Moore AW: Chromatin modification of Notch targets in olfactory receptor neuron diversification. Nat Neurosci 2012, 15:224-233.
• [55]Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM: Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
• [56]Ku CS, Naidoo N, Wu M, Soong R: Studying the epigenome using next generation sequencing. J Med Genet 2011, 48:721-730.
• [57]Rakyan VK, Down TA, Balding DJ, Beck S: Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011, 12:529-541.
• [58]Johannessen Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
• [59]Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL: Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010, 122:1-9.
• [60]Peedicayil J, Kumar A: Time for clinical trials of epigenetic drugs in psychiatric disorders? Br J Clin Pharmacol 2012, 73:309-310.